Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Financial Fact:
CONSOLIDATED NET INCOME: -761.74M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
CONSOLIDATED NET INCOME: -761.74M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q1 EPS of $0.87, in-line with the analyst estimate of $0.87. Revenue for the quarter came in at $691 million versus the consensus estimate of $700.34 million.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Endo Pharmaceuticals Holdings reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Endo Pharmaceuticals Holdings (ENDP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
